The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Subjects:

Comparison of densitometric, biochemical, and hormonal variables, and bone turnover markers of EBF + 6 months versus EBF + one year postpartum. by Larissa Brazolotto Ferreira (17671168)

Subjects:

Comparisons between densitometric, biochemical, and hormonal variables and bone remodeling markers of exclusive breastfeeding mothers (EBF) 15 days postpartum and the same EBF moth... by Larissa Brazolotto Ferreira (17671168)

Subjects:

Anthropometric, nutritional, and variable assessments of lean mass and fat mass obtained by DXA of exclusive breastfeeding mothers (EBF), at pre-pregnancy, baseline (15 days), and... by Larissa Brazolotto Ferreira (17671168)

Subjects:

Open data. by Larissa Brazolotto Ferreira (17671168)

Subjects:

The influence of 5-HT in mice serum on <i>Plasmodium</i> infection in mosquitoes. by Li Gao (131516)

Subjects:

Failure modes of joint surfaces under different τ₁of group C specimens under the UNLCSL path. by Zhezhe Zhang (19704587)

Subjects:

Loss of life expectancy by age group and stage of colorectal cancer and change if detected after one year. by Hiroaki Saito (24514)

Subjects:

<b> </b> Rate of brain weight to body weight in different experimental groups. AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate.... by Atefeh Sadeghi (21253051)

“…AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate. …”

Post-hoc analysis for visit-wise differences in dual-task learning. Significant differences between visits are indicated with an asterisk (*). by Swati M. Surkar (8399427)

List of primers used in this study. by Haotian Ma (11100492)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects: